The CJC-1295 research record, read one evidence state at a time.

What the human studies measured

The human record for CJC-1295 is small, early, and consistent. In healthy adults, single subcutaneous doses of 30 or 60 micrograms/kg produced dose-dependent 2- to 10-fold increases in mean plasma growth hormone lasting six days or more, and 1.5- to 3-fold increases in IGF-1 lasting nine to eleven days ^[1]. After multiple doses, IGF-1 remained above baseline for up to 28 days, and the analysis estimated a CJC-1295 half-life of 5.8 to 8.1 days ^[1].

A second study sharpened the picture. In healthy men aged 20 to 40, a single subcutaneous dose of 60 or 90 micrograms/kg raised basal GH approximately 7.5-fold, mean GH by about 46%, and IGF-1 by about 45% one week later — while the frequency and amplitude of pulsatile GH secretion were unchanged ^[3]. That last point is the structurally interesting one: under continuous stimulation by a long-acting GHRH analog, the pituitary kept releasing GH in pulses rather than as a flat plateau ^[3]. A later proteomic study in eleven healthy young men found reproducible serum protein shifts that correlated with the IGF-1 response, offering candidate biomarkers of GH/IGF-1-axis activation ^[5].

How strong is the evidence?

Strong on kinetics, thin on outcomes. The pharmacokinetic and pharmacodynamic behavior of CJC-1295 — how much GH and IGF-1 it raises, for how long, by which mechanism — is documented in peer-reviewed human studies ^[1][3]. That is the confirmed core of any honest CJC-1295 review.

How strong is the evidence?

Limited. The published human record consists of early-phase pharmacokinetic studies in small groups of healthy volunteers (Teichman 2006; Ionescu and Frohman 2006). A ConjuChem Phase 2 program in HIV-associated visceral obesity was discontinued, and no large efficacy or long-term safety trials in healthy adults exist ^[1]. Claims about body composition, muscle gain, or "anti-aging" outcomes are not supported by controlled human outcome data — they extrapolate from the GH/IGF-1 biomarker response.

That is the whole appraisal: the biomarker response is real and reproducible; the downstream clinical outcomes in healthy adults are unstudied. A research review that treats those two states as one is the single most common error in the popular literature on this compound.

The rat study that proved the design

The DAC concept was validated before any human dosing. A series of hGRF(1-29) analogs carrying a C-terminal maleimidopropionyl-lysine handle were screened; the lead candidate, CJC-1295, combined four DPP-IV-protective substitutions with covalent bioconjugation to circulating serum albumin ^[2]. In Sprague-Dawley rats it produced a 4-fold increase in GH area-under-the-curve over two hours versus the unconjugated peptide, remained detectable in plasma beyond 72 hours, and showed enhanced in-vitro stability against dipeptidylpeptidase-IV ^[2].

The mouse work then closed the loop on dosing frequency. In GHRH-knockout mice, 2 micrograms of CJC-1295 every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective; treatment also raised pituitary GH mRNA ^[4]. Together these studies establish the mechanistic claim: a long-acting, albumin-bound GHRH analog can drive the GH axis on an infrequent schedule ^[2][4].

What is a GHRH analog?

Reading CJC-1295 well means reading its class.

What is a GHRH analog?

A GHRH analog is a synthetic molecule that mimics growth-hormone-releasing hormone — the hypothalamic signal that tells the pituitary to make and release growth hormone. CJC-1295, sermorelin, and tesamorelin are all GHRH analogs; they bind the GHRH receptor (a class B G-protein-coupled receptor) on pituitary somatotrophs and activate the Gs/cAMP/PKA pathway that drives GH gene transcription ^[3]. The released GH then acts on hepatic GH receptors to raise IGF-1.

A 2024/2025 Nature Reviews Endocrinology review synthesizes the pharmacology of GHRH and its synthetic analogues — the class that includes CJC-1295 — describing receptor signaling, the rationale for long-acting analog design, and the therapeutic and investigational landscape ^[13]. The closest FDA-approved comparator in the class is tesamorelin, studied in HIV-associated fat accumulation; CJC-1295 itself has no approved indication ^[1].

CJC-1295 and ipamorelin: the two-receptor rationale

The most-discussed CJC-1295 pairing is with ipamorelin, and the rationale is mechanistic, not a clinical outcome trial. GHRH analogs and growth-hormone-releasing peptides (GHRPs) act through distinct receptors — the GHRH receptor and the ghrelin/GHS receptor — so co-administration can produce GH release greater than either alone ^[11]. Ipamorelin is the partner most often cited because it is a selective GH secretagogue with quantified pharmacokinetic-pharmacodynamic behavior ^[11].

Does CJC-1295 and ipamorelin work?

GHRH analogs and GHRPs act through distinct receptors and synergize, so co-administration produces greater acute GH release than either alone. Published data are on the acute GH/IGF-1 response, not on long-term body-composition outcomes in healthy adults.

What is CJC-1295 ipamorelin?

A research pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin). Because the two act on different receptors, co-administration produces greater GH release than either alone — the rationale behind the combination.

How much CJC-1295 / ipamorelin should I take?

There is no validated human dose for the combination. Community "protocols" pair fixed microgram amounts of each, but these are not derived from controlled human trials; the published basis is only the acute two-receptor GH synergy seen when a GHRH analog and a GHRP are co-administered.